Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HINT1 | P49773 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40775 | 1.00 | HPGD (0.72) | HPGDPAX8LMNATP53HINT1 | |
| SCHEMBL18512872 | 1.00 | HPGD (0.72) | HPGDPAX8LMNATP53HINT1 | |
| SCHEMBL18512870 | 1.00 | HPGD (0.72) | HPGDPAX8LMNATP53HINT1 | |
| SCHEMBL14946393 | 1.00 | HPGD (0.72) | HPGDPAX8LMNATP53HINT1 | |
| SCHEMBL387030 | 1.00 | HPGD (0.72) | HPGDPAX8LMNATP53HINT1 | |
| SCHEMBL25101150 | 0.99 | HPGD (0.70) | HPGDPAX8LMNATP53HINT1 | |
| SCHEMBL1707040 | 0.89 | HPGD (0.57) | HPGDPAX8HINT1IMPDH2IMPDH1 | |
| SCHEMBL21831928 | 0.89 | HPGD (0.57) | HPGDPAX8HINT1IMPDH2IMPDH1 | |
| SCHEMBL7246469 | 0.89 | HPGD (0.57) | HPGDPAX8HINT1IMPDH2IMPDH1 | |
| SCHEMBL5950289 | 0.89 | HPGD (0.57) | HPGDPAX8HINT1IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170044619-A1 | PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-02-16 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | HPGD 2978/4885PAX8 1390/4885LMNA 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.